News

May 23, 2024

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer

April 24, 2024

AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024

April 9, 2024

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024

April 8, 2024

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors

March 19, 2024

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC

March 5, 2024

AffyImmune Therapeutics to Present Poster at 2024 American Association for Cancer Research Annual Meeting